tirzepatide by eli lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Eli Lilly's weight loss drug

The measurement of regional large artery stiffness should be expanded in the future for pathomechanistic studies via a multimodal vascular imaging approach in combination with vascular biomarkers (e.g., extracellular vesicles, blood biomarkers for inflammation, and endothelial dysfunction)

Only medication acquisition costs were included in the analysisthe costs of diabetes-related complications were not included, as these would not be expected to differ over the 1-year time horizon, and neither micro- nor macrovascular complications were assessed in SUSTAIN 2 or SUSTAIN 7

1.9 units/day, LS mean change 3.7 units/day

Severe (Rare): Acute pancreatitis, severe gallbladder disease (cholecystitis), or acute kidney injury caused by dehydration from severe GI side effects